Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib

Autoři	FIALA Ondrej PESEK Milos FINEK Jindrich TOPOLCAN Ondrej RACEK Jaroslav SVATON Martin KUCERA Radek MINARIK Marek BENESOVA Lucie BORTLÍČEK Zbyněk CHLOUPKOVÁ Renata POPRACH Alexandr BUCHLER Tomas
Rok publikování	2016
Druh	Článek v odborném periodiku
Časopis / Zdroj	Anticancer Research
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Obor	Onkologie a hematologie
Klíčová slova	Lactate dehydrogenase; LDH; lung cancer; NSCLC; EGFR-TKI; erlotinib; prediction; biomarker
Popis	Background: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. Results: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). Conclusion: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.